Tissue Repair
Chonluten
Khavinson lung bioregulator
Khavinson short peptide bioregulator
This Chonluten entry draws on 3 cited sources published 2020 to 2021. The evidence available is graded Russian Research on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Khavinson short peptide bioregulator
- Drug class
- Tissue Repair
- Structure
- Tripeptide Glu-Asp-Gly
- Route
- Oral / Intranasal
- Half-life
- Short (minutes)
- Evidence tier
- Russian Research
- Availability
- Research
- Research depth
- 3 indexed citations →
Mechanism of action
Tissue-specific gene expression modulation in respiratory epithelium
Reported areas of research
Lung/bronchial epithelial support; mucosal function
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Oral capsule 1-2x daily
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Limited Western evidence
Compared with
Chonluten has published head-to-head comparisons with 16 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
- Chonluten vs Bronchogen
- Chonluten vs Cardiogen
- Chonluten vs Cartalax
- Chonluten vs Cortagen
- Chonluten vs Crystagen
- Chonluten vs Epitalon
- Chonluten vs Livagen
- Chonluten vs Ovagen
- Chonluten vs Pancragen
- Chonluten vs Pinealon
- Chonluten vs Prostamax
- Chonluten vs Testagen
- Chonluten vs Thymagen
- Chonluten vs Vesilute
- Chonluten vs Vesugen
- Chonluten vs Vilon
Frequently asked questions
What dosing is reported for Chonluten in research literature?
Published peptide research reports the following dosing approach for Chonluten: Oral capsule 1-2x daily. This is a research reference, not a clinical recommendation.
How is Chonluten administered in research?
Chonluten is administered via the following routes in published studies: Oral / Intranasal.
What is the reported half-life of Chonluten?
No measured half-life for Chonluten is reported in the literature catalogued here. The catalog describes it as: Short (minutes).
Is Chonluten FDA-approved?
No. Chonluten is not an FDA-approved drug. PeptideHelper.org catalog status: Research.
What level of evidence supports Chonluten?
The current evidence base for Chonluten is best characterised as: Russian Research. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Chonluten?
Known concerns reported in the literature for Chonluten include: Limited Western evidence. Always consult a qualified clinician before any human use.
Is there anyone who should not use Chonluten?
No formal contraindications are established for Chonluten, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Limited Western evidence. Always consult a qualified clinician before any human use.
How does Chonluten work?
The mechanism of action reported for Chonluten in the literature: Tissue-specific gene expression modulation in respiratory epithelium.
What is Chonluten studied for?
Chonluten has been studied in the published literature for: Lung/bronchial epithelial support; mucosal function. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Chonluten?
Chonluten is classified as: Khavinson short peptide bioregulator. Also known as: Khavinson lung bioregulator.
Drug class
- Khavinson peptides, see all peptides tagged Khavinson.
Research focus area
All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.
Primary sources
- Khavinson VK et al. Peptide regulation of gene expression — a systematic review. Molecules 2021. PMID 34834147
- Khavinson V et al. Peptide regulation of cell differentiation. Stem Cell Rev Rep 2020. PMID 31808038
- Note: Primary literature on this peptide is published largely in Russian gerontology journals (Adv Gerontol, Bull Eksp Biol Med). English-indexed sources are limited to comprehensive Khavinson-laboratory reviews; entry confidence is correspondingly lower.
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…